• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Affimed N.V.

    5/1/25 4:05:20 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    NT 20-F 1 d847700dnt20f.htm NT 20-F NT 20-F
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

    SEC File Number: 001-36619

    CUSIP Number: N01045207

     

    (Check one):   

    ☐ Form 10-K  ☒ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q

    ☐ Form 10-D  ☐ Form N-SAR  ☐ Form N-CSR

      For Period Ended: December 31, 2024
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      ☐ Transition Report on Form N-SAR
      For Transition Period Ended:  

     

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not Applicable

     

       

     

    PART I – REGISTRANT INFORMATION

    Affimed N.V.

    Full Name of Registrant

    Not Applicable

    Former Name if Applicable

    Gottlieb-Daimler-Straße 2

    Address of Principal Executive Office (Street and Number)

    68165 Mannheim, Germany

    City, State and Zip Code

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒     (a)  

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

      (b)  

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period.

    Affimed N.V. (the “Company”) was unable to file, without unreasonable effort and expense and within the prescribed time period, its Annual Report on Form 20-F for the year ended December 31, 2024 (the “Form 20-F”). The Company must enhance its liquidity position such that management can conclude that the Company will, on a more-likely-than-not basis, have sufficient liquidity to operate as a going concern for at least twelve months from the expected issuance date of the Form 20-F.

    The Company preliminarily estimates that, as of December 31, 2024, cash, cash equivalents and investments were approximately €13.0 million. The Company expects that its cash-runway is sufficient to fund its operations until the end of Q2 2025. This represents an update from the Company’s prior guidance, which projected cash-runway into Q4 2025. The Company is engaging in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital, however, there can be no assurance that the Company will be successful in raising additional capital.

    Under German law, management is required to file for insolvency without undue delay if the company is deemed either illiquid or over-indebted. A company is generally considered illiquid if it is unable to meet its due payment obligations and the resulting liquidity shortfall cannot be resolved within the next three weeks. A company is generally considered over-indebted if management concludes that the company is, on a more-likely-than-not basis, unable to meet its payment obligations as and when they fall due within the next twelve months, unless the liquidation value of its assets exceeds the face value of its liabilities plus provisions for the cost of liquidation. As a result, the obligation to file for insolvency may arise even before the Company has fully depleted its available cash reserves. While, as of the date of this Form 12B-25, management continues to believe that the Company is more likely than not to raise additional capital sufficient to continue as a going concern for at least twelve months from the expected issuance date of the Form 20-F, there can be no assurance that such capital will in fact be obtained or that a mandatory insolvency filing can ultimately be avoided.

    The Company plans to file the Form 20-F as soon as practicable but cannot offer assurance that it will do so within the fifteen calendar days following the prescribed due date in accordance with Rule 12b-25.

    PART IV — OTHER INFORMATION

     

    (1)       Name and telephone number of person to contact in regard to this notification.
        Shawn Leland          (49)          621-560-030
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes ☒ No ☐
         
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

    PRELIMINARY ESTIMATES

    This Form 12b-25 contains certain preliminary estimated financial information of the Company as of the year ended December 31, 2024 and certain preliminary information related to the Company’s 2025 outlook. Such preliminary information is not yet finalized, remains subject to completion and reflects management’s current estimates. The preliminary estimated financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed) and should not be viewed as a substitute for financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board. While carrying out such procedures, the Company may identify items that require adjustments to the preliminary estimates set forth in this Form 12b-25. In addition, other developments may arise between the date of this Form 12b-25 and the date that the Company reports the results for the year ended December 31, 2024, which may cause actual results to be different than the preliminary estimates set forth in this Form 12b-25. There can be no assurance that the Company’s final results will not differ from these preliminary estimates, which are forward-looking statements based only on currently available information as of the date hereof. Therefore, you should not place undue reliance on these preliminary estimates nor should you view these as a substitute for the Company’s audited financial statements for the year ended December 31, 2024. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary results, nor have they expressed any opinion or any other form of assurance on the preliminary results.

    The preliminary information is presented for informational purposes only and does not purport to represent the Company’s financial condition or results of operations for any future date or period. As a result, caution should be exercised in relying on this information and no inferences should be drawn from this information regarding financial or operating data not provided.

    FORWARD-LOOKING STATEMENTS

    This Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “plan,” “will,” “believe,” “anticipate,” “doubt,” “expect,” “intend,” and similar terms and phrases are used in this Form 12b-25 to identify forward-looking statements, including statements regarding the Company’s ability to file the Form 20-F within the time period prescribed by Rule 12b-25, discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital and the Company’s expectations regarding its financial and business performance, including the Company’s preliminary financial results for the year ended December 31, 2024, the Company’s preliminary 2025 outlook regarding its cash-runway and the Company’s ability to continue as a going concern. Actual results may differ materially from the results anticipated by the Company’s forward-looking statements due to certain risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

     

     

    Affimed N.V.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 1, 2025     By:   /s/ Shawn Leland
        Name:   Shawn Leland
        Title:   Chief Executive Officer

     

     
     
    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    10/12/2021$13.00 → $12.00Outperform
    SVB Leerink
    9/30/2021$12.00Buy
    Stifel
    More analyst ratings

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

      MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations. Det

      4/23/25 10:05:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

      MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3

      4/21/25 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

      12/12/22 7:32:36 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Affimed Therapeutics from Buy to Hold and set a new price target of $2.00 from $9.00 previously

      10/10/22 7:08:28 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo resumed coverage on Affimed Therapeutics

      Wells Fargo resumed coverage of Affimed Therapeutics with a rating of Overweight

      8/18/22 10:27:27 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Affimed Appoints Shawn M. Leland as Chief Executive Officer

      MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais

      9/3/24 7:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board

      HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he

      6/22/23 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

      HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine

      6/16/21 7:04:39 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Financials

    Live finance-specific insights

    See more
    • Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

      MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

      12/9/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Reports Third Quarter 2024 Financial Results & Business Update

      AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

      11/14/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

      MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

      11/6/24 6:30:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Affimed N.V.

      SC 13G - Affimed N.V. (0001608390) (Subject)

      10/24/24 2:49:52 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/24 4:07:21 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

      SC 13G/A - Affimed N.V. (0001608390) (Subject)

      2/13/24 1:20:05 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Affimed N.V.

      NT 20-F - Affimed N.V. (0001608390) (Filer)

      5/1/25 4:05:20 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      4/21/25 8:32:58 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

      SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

      2/14/25 8:18:09 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care